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cancer cases was based on the National Cancer Register con-
ducted by the Institute of Oncology in Poland. All calculations
were performed for 2006 (1 Euro = 3.8 PLN. RESULTS: Cost
of yearly treatment of one standard patient was 13.270 PLN
(€3.492) from public payer and 26.429 PLN (€6.955) from soci-
etal perspective respectively. Taking into account cervical cancer
prevalence in Poland (3.439 cases in 2003) and cost per each
case, the total burden of cervical cancer in 2006 was 45.635.530
PLN (€12.009.350) from public payer and 92.290.068 PLN
(€24.286.860) from societal perspective respectively. CONCLU-
SIONS: Cervical cancer is a fatal and costly disease. Indirect
costs are about 50% of total burden of cervical cancer in Poland
in 2006.
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OBJECTIVE: To evaluate the management and the management
cost of follow-up of women with abnormal Pap result in 5 coun-
tries (UK, Australia, Germany, Spain & Italy). METHODS: A
retrospective chart review of resource use was conducted in 33
centres within the ﬁve countries. Historical data was collected
on >3000 women with an abnormal Pap smear over a 2-year
treatment and follow-up period starting from year 2002. The
study population was stratiﬁed to include a minimum number of
subjects per cytology category: 35% mild, 25% moderate, 25%
severe dyskaryosis, and 15% cervical cancer. If not enough
cancer cases were enrolled in a country additional cases were
searched for. Unit costs for treatment were calculated from
country-speciﬁc cost databases. We compare overall and
between-countries overall age and age distribution; correlation
between cytology and histology; resource use and cost per his-
tology group after purchasing power parity adjustment.
RESULTS: Overall mean age of patients (n = 3380) was 36.3 y
old (min = 16 y, max = 90 y). Patients with histologically con-
ﬁrmed invasive cancer (n = 333) were on average 48.8 years (min
= 21 y, max = 85 y). Proportion of patients in each conﬁrmed
pre-cancer group was: CIN-1 = 17.1%; CIN-2 = 18.6%; CIN-3
= 29.9%. Negative evaluations after ﬁrst inspection and/or
biopsy were 24% and cancer cases seen and conﬁrmed were
9.9%. The correlation coefﬁcient between cytology and histol-
ogy ﬁndings overall was 62.6, but varied widely across countries.
Resource use such as number of pap smears per stage, colpo-
scopies, and LEEPs shows signiﬁcant differences across countries
and per histology stage (p < 0.05). The initiation of treatment
and type of treatment per histology stage varied considerably
within each country and across the aggregate database. CON-
CLUSION: Weak correlations between cytology and histology
across all countries were observed. Average cost per histology
varies by country and can be substantial. Large cost SDs per his-
tology stage indicate that it remains difﬁcult to standardise treat-
ment for early stages.
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OBJECTIVES: Renal cell carcinoma (RCC) represents 2–3% of
all malignancies, and is associated with limited treatment options
and low survival rates (median survival for advanced metastatic
disease is estimated at 8–12 months). Despite its importance,
data on the economic burden of RCC are limited. METHODS:
A global, prevalence-based burden-of-illness model was devel-
oped and used to estimate the annual, societal economic burden
of RCC in selected European countries (UK, Spain, France, and
Germany). Key relationships represented in the model include
the annual numbers of patients treated for RCC by age group
and cancer stage; utilization of cancer-speciﬁc treatments; unit
costs of these treatments; work-days missed by these patients,
and wage rates. Local-area data sources were used to populate
the model parameters for each country. Methodological differ-
ences across countries resulting from differences in data avail-
ability are explained. RESULTS: The annual numbers of cases
of RCC include 24,834 in the UK, 3945 in Spain, 35,714 in
France, and 59,864 in Germany. Corresponding estimates of the
aggregate annual burden of RCC (€ 2005) are €541 million,
€41.8 million, €171 million, and €1.6 billion, respectively (per-
patient costs of €21,792, €10,607, €4781, and €26,397). Health
care costs account for between 66% and 89% of the burden in
each country, with lost productivity accounting for the remain-
der. Inpatient care for major surgery, radiofrequency ablation,
arterial embolization, systemic therapy (chemotherapy, radia-
tion, immunotherapy), and associated complications is the
largest driver of health care costs, accounting for approximately
80% or more of the burden in each country. Sensitivity analyses
indicated that results were most sensitive to assumptions regard-
ing health care utilization and unit costs of treatments. 
CONCLUSIONS: The economic burden of RCC in Europe is
substantial. Interventions to reduce the prevalence of RCC have
the potential to yield considerable economic beneﬁts to EU
health systems.
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OBJECTIVES: Trastuzumab (Herceptin®) combined to
chemotherapy has demonstrated signiﬁcant improvement in time
to progression and survival in metastatic breast cancer patient
overexpressing the receptor of the human growth factor (HER-
2). Herceptin® has recently received a new indication as an 
adjuvant therapy in localised invasive breast cancer and the 
cost-effectiveness of this new add-on therapy needs to be evalu-
ated. METHODS: An analytic Markov Model was established
based on the results of the pivotal clinical study (HERA) and
expert opinion to simulate for an early breast cancer patient 
the course of disease until death. The health states included 
loco-regional and distant recurrences (metastasis), cardiac events
(side-effects), disease free survival and death respectively. This
simulation model projected long-term clinical outcomes and
costs, of adding Herceptin® during one year sequentially to stan-
dard adjuvant therapy versus standard alone (observation).
According to current practices in France, Herceptin® was also
supposed to be used in case of distant recurrences in both arms.
Improvements in lifetime quality adjusted life years (QALY) were
also estimated. Transition probabilities were adjusted on HERA
results. Yearly costs of each health state came from published
sources and from detailed costs observed in one French Oncol-
ogy Centre (G.-F. Leclerc in Dijon). Direct costs and outcomes
were projected over patients’ lifetimes from a French Sickness
Fund perspective. They were both discounted at 3% annually.
Sensitivity analysis was performed. RESULTS: For 1000 patients
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with a 10-year follow-up, an adjuvant therapy with Herceptin®
would avoid 49.7 loco-regional recurrences, 179.5 distant recur-
rences and 133.4 deaths. Incremental cost-utility ratio of Her-
ceptin® was €18,282/QALY gained at lifetime horizon, which is
well below the commonly accepted threshold of €45,000/QALY
gained. CONCLUSIONS: Utilization of Herceptin® as an adju-
vant therapy in patients with primary HER-2 positive breast
cancer improves patient survival with an acceptable cost-utility
ratio in the French setting.
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OBJECTIVES: To estimate the cost-effectiveness of rituximab
plus cyclophosphamide, vincristine, and prednisone (RCVP)
compared to CVP alone in previously untreated NHL patients
with advanced follicular lymphoma from a Canadian perspec-
tive. METHODS: A cost-utility analysis was performed from a
Ministry of Health perspective over a 10-year time horizon using
a Markov health state transition model. All patients (mean age
53 years) enter the model in a progression-free health state. Sur-
vival was estimated from Kaplan-Meier curves from a published
phase III trial of RCVP versus CVP in patients with stage III or
IV follicular lymphoma (median follow-up 31 months) and data
from the Scotland and Newcastle Lymphoma Group (SNLG)
registry using a line of best ﬁt approach. Utilities for quality of
life were assessed using the EQ-5D in a population of NHL
patients from the UK. Direct annual medical costs including drug
acquisition, administration and preparation were estimated from
published sources. All costs are reported in 2005 CAD. Costs
and outcomes were discounted at a rate of 5%. In order to
address uncertainty in point estimates, one way sensitivity analy-
ses were also performed. RESULTS: The addition of rituximab
to CVP resulted in an additional 1.3 years of progression free
survival and 0.58 quality adjusted life years (QALYs) over CVP
alone. The cost of RCVP therapy was $43,445 compared to
$22,891 for CVP. The incremental cost-utility ratio was
$35,753/QALY. Results from one-way sensitivity analyses
ranged from a low of $22,079/QALY to a high of $55,338/
QALY. CONCLUSION: The addition of rituximab to a regimen
of CVP represents a cost-effective treatment alternative in previ-
ously untreated NHL patients according to conventionally
accepted ratios.
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OBJECTIVES: The TAC adjuvant chemotherapy regimen 
compared to FAC improves the disease free survival (DFS) and
overall survival (OS) rates signiﬁcantly in women with operable
node positive breast cancer, but the cost-effectiveness of this
better efﬁcacy was not evaluated. METHODS: We developed 
a model describing the clinical history of women with node 
positive breast cancer that projected improvements in lifetime
quality adjusted life years (QALY), long-term costs, and cost-
effectiveness of the adjuvant treatment TAC compared to FAC.
The base case was a 50 years old woman with unilateral node
positive breast cancer submitted to mastectomy and without
metastasis. Transition probabilities came from the BCIRG 001
study and other major studies; the quality of life for each health
state was based on the medical literature. The local management
and costs of each health state was based on a Delphi panel
according to the private health care perspective. Outcomes were
discounted at 3% annually. Sensitivity analyses and a second
order Monte Carlo simulation were performed. RESULTS: The
lifetime horizon analysis showed: DFS of 32.5% and 29% and
OS of 38% and 33%, for TAC and FAC, respectively; TAC
increased life expectancy (LY) in 1.20 years and in quality
adjusted life years (QALY) there was a 1.08 year gain, in com-
parison to FAC; the incremental cost per QALY was R$9476.92;
the FAC group expense in the metastasis state, in ﬁfteen years,
was bigger than the whole cost for the treatment of recurrence
states, for a whole life, with TAC; the Monte Carlo simulation
showed that TAC is cost-effective 98% of the times and is cost-
saving 18% of the times. CONCLUSION: Improvements in DFS
and OS with adjuvant TAC regimen in women with operable
node positive breast cancer improves patient outcomes in terms
of LY and QALY with an acceptable cost-effectiveness ratio in
Brazil.
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OBJECTIVES: Fulvestrant (Faslodex) is a well-tolerated estro-
gen receptor antagonist that is at least as effective as anastrozole
in patients who have progressed or recurred on tamoxifen. A
health economic model was developed to estimate the incre-
mental cost per quality adjusted life year (QALY) gained when
fulvestrant is included as an additional endocrine therapy step
for postmenopausal women with hormone receptor positive
(HR+) advanced breast cancer (ABC). METHODS: A seven-state
Markov model was developed from a UK NHS perspective. This
followed patients over their treatment for ABC, simulated over
a 10-year time horizon. The model compared the costs and ben-
eﬁts of two cohorts of patients—one with and one without the
addition of fulvestrant to the endocrine treatment sequence.
Clinical data were collated from published trials. Resource uti-
lization data were obtained from published literature and a
survey of ﬁve UK physicians. Unit costs were taken from pub-
lished sources. Each Markov cycle lasted 28 days. Major
assumptions were validated via a survey of seven UK physicians.
Costs and beneﬁts were discounted at 3.5%. The robustness 
of results was tested using a probabilistic sensitivity analysis.
RESULTS: In a cohort of 1000 postmenopausal women with
HR+ ABC, the model suggested that a treatment sequence with
fulvestrant as a third endocrine therapy step leads to a gain 
of 41 QALYs at an additional cost of ≤69,910, as compared 
to a sequence without fulvestrant. The estimated incremental
cost-effectiveness ratio (ICER) of including fulvestrant in the
endocrine treatment sequence was ≤1705 per QALY. Cost-
effectiveness acceptability curves indicated over a 70% pro-
bability that the cost per QALY gained would be lower 
than ≤20,000, a commonly accepted UK threshold for cost-
effectiveness. CONCLUSIONS: Based on this economic model,
the use of fulvestrant as an additional endocrine therapy step in
the treatment of HR+ ABC is a cost-effective treatment strategy.
